A New Zealand company is producing a probiotic feed additive system (including a starter and finisher product) for use between birth and weaning which claims to improve rumen development and feed conversion of the calf. It also claims to provide an increase in the yield of milk solids produced by the animal during subsequent lactations.
A technology that allows farmers to rapidly (12-18hrs) identify the causative agent in mastitic cows, and make informed and timely decisions on appropriate follow-on actions. The technology is designed to be used on-farm and utilises a simple and easy to use plate system. An opportunity exists for a third party to acquire rights to the technology.
This company is reformulating existing drugs that are off-patent into oral spray formats that can become patentable products. Delivery of existing dog and cat medication through the oral mucosa may allow pet owners to deliver drugs to their animals more easily.
This company is developing a gel for preventing postoperative adhesions. This common complication occurs in multiple types of surgery and can result in disorders such as chronic pain, scarring, and obstructions. While the company is commercialising this product for humans, it also has potential for the same complication in companion and high value animals.
Company with a non-antibiotic preventative and treatment effective against bacterial gastroenteritis (scours) in animals. Based on a fruit-derived active, the company has strong data from porcine uses of its product. We see an opportunity here for licensing of the current pig product or future applications, including for other animal species.
Researchers at an Australian University have discovered, developed and patented a novel class of small cyclic peptides (cyclotides) that are extremely stable and active against insects, nematodes and microbial pests. The molecules can be produced recombinantly in plants.